Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | METAP2 | P50579 | 2/20 | 0.47 |
| ▸ | METAP1 | P53582 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14720630 | 1.00 | CYP19A1 (0.52) | CYP19A1METAP2METAP1MEN1KMT2A | |
| SCHEMBL28968076 | 0.82 | CYP19A1 (0.56) | CYP19A1MEN1KMT2ALMNAL3MBTL1 | |
| SCHEMBL10901068 | 0.77 | CYP19A1 (0.73) | CYP19A1MEN1KMT2ALMNACYP2D6 | |
| SCHEMBL16811757 | 0.76 | CASP1 (0.49) | MEN1KMT2ACASP1LMNASSTR4 | |
| SCHEMBL10920938 | 0.76 | CASP1 (0.49) | MEN1KMT2ACASP1LMNASSTR4 | |
| SCHEMBL7038146 | 0.76 | ACP3 (0.39) | METAP2METAP1MEN1KMT2AACP3 | |
| SCHEMBL7802112 | 0.76 | KCNA5 (0.52) | METAP2METAP1MEN1KMT2AMAPT | |
| SCHEMBL7871934 | 0.76 | ACP3 (0.44) | METAP2METAP1ACP3SSTR4 | |
| SCHEMBL8095115 | 0.75 | ACP3 (0.39) | CYP19A1METAP2METAP1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7799081 | 0.75 | KCNA5 (0.51) | METAP2METAP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512155-B2 | Chiral phosphines for palladium-catalyzed asymmetric α-arylation of ester enolates to produce tertiary stereocenters in high enantioselectivity | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-12-06 | — | — | US | disclosed |
| US-20150166586-A1 | CHIRAL PHOSPHINES FOR PALLADIUM-CATALYZED ASYMMETRIC ALPHA-ARYLATION OF ESTER ENOLATES TO PRODUCE TERTIARY STEREOCENTERS IN HIGH ENANTIOSELECTIVITY | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2015-06-18 | — | — | US | disclosed |
| WO-2013028132-A9 | CHIRAL PHOSPHINES FOR PALLADIUM-CATALYZED ASYMMETRIC ALPHA-ARYLATION OF ESTER ENOLATES TO PRODUCE TERTIARY STEREOCENTERS IN HIGH ENANTIOSELECTIVITY | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013028132-A1 | CHIRAL PHOSPHINES FOR PALLADIUM-CATALYZED ASYMMETRIC ALPHA-ARYLATION OF ESTER ENOLATES TO PRODUCE TERTIARY STEREOCENTERS IN HIGH ENANTIOSELECTIVITY | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166586-A1 | CHIRAL PHOSPHINES FOR PALLADIUM-CATALYZED ASYMMETRIC ALPHA-ARYLATION OF ESTER ENOLATES TO PRODUCE TERTIARY STEREOCENTERS IN HIGH ENANTIOSELECTIVITY | EPHA8, DAGLA, TEC | CYP19A1 2288/4885METAP2 4321/4885METAP1 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.